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ABSTRACT
Brain tumours kill more children and adults under 40 than any other cancer. 
Around half of primary brain tumours are glioblastoma multiforme (GBMs) where 
treatment remains a significant challenge.GBM survival rates have improved little over 
the last 40 years, thus highlighting an unmet need for the identification/development 
of novel therapeutic targets and agents to improve GBM treatment. Using archived and 
fresh glioma tissue, we show that in contrast to normal brain or benign schwannomas 
GBMs exhibit re-expression of FANCD2, a key protein of the Fanconi Anaemia (FA) 
DNA repair pathway, and possess an active FA pathway. Importantly, FANCD2 
expression levels are strongly associated with tumour grade, revealing a potential 
exploitable therapeutic window to allow inhibition of the FA pathway in tumour cells, 
whilst sparing normal brain tissue. Using several small molecule inhibitors of the 
FA pathway in combination with isogenic FA-proficient/deficient glioma cell lines 
as well as primary GBM cultures, we demonstrate that inhibition of the FA pathway 
sensitises gliomas to the chemotherapeutic agents Temozolomide and Carmustine. 
Our findings therefore provide a strong rationale for the development of novel and 
potent inhibitors of the FA pathway to improve the treatment of GBMs, which may 
ultimately impact on patient outcome.
INTRODUCTION
Brain tumours are the biggest cancer killers of 
the under 40s with over 400,000 new cases diagnosed 
worldwide each year. They also represent the commonest 
site for solid tumours in childhood under the age of 15 
[1]. However, brain tumour research has received far less 
funding than many other cancers and patient survival has 
improved little over the last 40 years (Cancer Research 
UK, Brain Tumour Research and The Brain Tumour 
Charity). There is therefore an unmet need for the 
development of novel targets and agents to improve GBM 
treatment.
Around half of primary brain tumours are high-
grade malignant astrocytomas, also known as glioblastoma 
multiforme (GBM). Treatment of GBM remains a 
significant challenge with a median patient survival 
of ~1yr. Current treatments are limited by anatomical 
constraints e.g. proximal neural areas, high resistance 
to radio-/chemotherapy and the blockading effect of the 
blood-brain barrier to systemically administered agents 
[1]. In addition to surgery, standard treatment for these 
tumours consists of chemotherapeutic agents such as 
Temozolomide (TMZ), Carmustine (BCNU) and/or 
radiotherapy regimes. Previous work has suggested that 
up-regulation of DNA response (DDR) pathways in GBM 
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may contribute to some of the relative ineffectiveness of 
these agents [2, 3]. However, the underlying molecular 
mechanisms driving inherent or acquired resistance of 
GBM to DNA damaging agents has yet to be determined. 
There is therefore precedence for determination of 
expression levels/activity of DDR factors in GBM that 
could account for resistance to therapeutic agents, as well 
as highlighting novel drug targets as a means to augment 
the cytotoxicity of current therapeutic regimes.
The Fanconi Anaemia (FA) pathway is comprised 
of at least 16 proteins that promote the repair of lesions 
that impede DNA replication in order to preserve genome 
integrity [4-6]. As such, the FA pathway is activated 
during DNA replication or in response to the detection 
of replication-blocking lesions [7], and is therefore often 
down regulated in differentiated cells [8]. Consistent with 
this, previous studies have shown that highly proliferative 
tissues such as testis, tonsils and spleen exhibit high levels 
of FANCD2 and FANCA expression, yet non-proliferative 
tissues such as lung, liver, muscle and the brain exhibit 
minimal protein expression [9, 10]. Furthermore, a recent 
large-scale gene expression study revealed that at least 
11 of the FA genes exhibit increased expression at the 
mRNA level in GBM compared to normal brain tissue 
[11]. This raises the possibility that as brain tumours such 
as oligodenrogliomas and astrocytomas become more 
proliferative, they re-activate the FA pathway.
The FA pathway is activated in response to a variety 
of DNA damaging agents that impede DNA replication, 
where it acts to facilitate lesion repair and/or bypass, and 
co-ordinates recruitment and activity of other DNA repair 
pathways needed to repair such lesions [12]. As such, 
cells defective in the FA pathway are rendered sensitive 
to a variety of DNA crosslinking agents, making the 
FA pathway an attractive target for inhibition in cancer 
cells. In an attempt to identify novel inhibitors of the FA 
pathway (FAPi), several groups have carried out large-
scale small-molecule library screens [13-16]. These studies 
have revealed four FAPi that are currently commercially 
available; curcumin and its monoketone analogues EF-
24 & 4H-TTD, and the menadione analogue DDN [13-
16]. However, the mode of action of these compounds 
has not been elucidated to date, and curcumin may 
impact on multiple DNA repair pathways [17]. Pertinent 
to the treatment of GBM, the FA pathway is activated 
in response to alkylating agents such as Temozolomide 
(TMZ) and Carmustine (BCNU; [18]), and previous work 
has demonstrated that FA-deficient cells are more sensitive 
to TMZ and BCNU than FA-proficient cells [18, 19]. 
Given these previous findings, we hypothesised that the 
FA pathway would not be expressed/active in normal non-
proliferative brain tissue, but be re-activated in rapidly 
proliferating GBMs. As such, FA pathway inhibition 
in aggressive brain tumours may offer an exploitable 
therapeutic window to improve the treatment of GBM to 
currently used chemotherapeutic agents. 
Using both archived and fresh GBM tissue, we 
demonstrate that in contrast to normal brain tissue or 
benign Schwannomas, the key FA pathway protein 
FANCD2 is re-expressed and that the FA pathway is active 
in GBMs. Furthermore, expression levels of FANCD2 
strongly correlate with tumour grade. We also show that 
three separate small molecule FA pathway inhibitors 
sensitise GBMs (primary and established cultures) to both 
TMZ and BCNU irrespective of MGMT status. Our data 
therefore highlights a potential exploitable therapeutic 
window to increase the cytotoxicity of chemotherapeutic 
agents used to treat GBM, whilst sparing normal non-
cancerous brain tissue. 
RESULTS
The FA pathway is re-expressed and active 
in high-grade GBM, with FANCD2 protein 
expression associated with tumour grade
Given that the FA pathway responds to lesions that 
impede on-going DNA replication [12], is down-regulated 
in differentiated cells [8], expressed in highly proliferative 
tissue, but not expressed in normal brain tissue [9, 10]; 
we hypothesised that FA protein expression would be 
elevated in GBM and might potentially correlate with 
clinical grade. To test this, we quantified the expression of 
the key FA pathway protein FANCD2 [6] in 131 archived 
FFPE glioblastoma specimens collected at the Royal 
Hallamshire Hospital’s neuro-oncology department. 
As normal brain material is difficult to obtain, benign 
schwannomas served as a negative control for these 
experiments (Figure 1A). FANCD2 expressing cells were 
never detected in schwannomas and only 7% of grade 
II oligodendrogliomas exhibited FANCD2 expression 
(Figures 1A and 1B). However, 46% and 93% of grade 
III and grade IV gliomas respectively stained positive for 
FANCD2 expression (Figures 1A and 1B). Comparable 
data was obtained using a commercial tissue microarray, 
in which normal brain tissue was devoid of any FANCD2 
expression, and expression was more prevalent with 
increasing tumour grade (Figure 1C). In both experiments 
there was a significant association between the presence 
of FANCD2 expression and tumour grade (p<2x10-16 and 
p<1x10-4 respectively). Given these findings, we attempted 
to stratify overall survival of the Grade III patients 
with FANCD2 staining, but did not detect a significant 
correlation (data not shown). However, this cohort was 
very heterogeneous with some patients having undergone 
aggressive de-bulking surgery and radiotherapy, while 
others having just biopsy. Therefore, given the relatively 
small number of cases in this cohort and the differences in 
treatment regimes among them, it is perhaps not surprising 
that no prognostic correlation between FANCD2 staining 
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and patient survival could be ascertained at this time.
Consistent with the overall findings in our archived 
tissue samples, we observed negligible FANCD2 staining 
in one particular low-grade (radiology diagnosis) 
oligodendroglioma originally diagnosed in 2011 
(supplementary Figure 1B). This tumour was graded WHO 
II at biopsy later that year and immunohistochemical 
analyses revealed weak FANCD2 expression 
(supplementary Figure 1B). This patient was re-admitted 
in 2012 with biopsy proven transformation to grade III 
anaplastic astrocytoma from which we were again able to 
determine FANCD2 expression. Interestingly, the patient’s 
grade III tumour exhibited increased FANCD2 expression 
compared to the previous biopsy proven lower grade 
disease (supplementary Figure 1B). Even with the caveat 
that this is a single case, taken together with our analyses 
of over 165 normal, benign schwannomas and brain 
tumours derived from multiple patients (Figures 1A-C), 
our data reveal that FANCD2 expression is significantly 
associated with tumour grade. These findings therefore 
raise the possibility that the FA pathway is more active 
in high-grade gliomas, and may therefore contribute to 
chemotherapeutic resistance.
Even though we have determined that FANCD2 
expression increases with brain tumour grade, it does 
not indicate if the FA pathway is active in these tumours 
and could contribute to chemotherapeutic resistance 
mechanisms [19, 20]. To determine if the FA pathway is 
indeed active in high-grade glioma, we derived primary 
cultures from freshly resected grade III/IV gliomas 
(supplementary Figure 1C), using previously described 
protocols [21, 22]. In agreement with our findings in 
archived FFPE gliomas, all successfully established 
primary GBM cell cultures to date were found to express 
FANCD2 (Figure 1D and data not shown). Importantly, 
the FA pathway is active in these cells, as treatment of 
these primary cultures with the chemotherapeutic agent 
Temozolomide (TMZ) activated mono-ubiquitination of 
FANCD2 and re-localisation to nuclear foci (Figures 1D 
and supplementary Figure S1D). These are two key steps 
in activation of the FA pathway [23], and imply that the 
rest of the FA pathway is also expressed to sufficiently 
high levels to facilitate FANCD2 mono-ubiquitination/
re-localisation. Overall, these data are consistent with 
previous mRNA studies [11], and demonstrate that 
FANCD2 protein expression increases with glioma grade 
and is active and responsive to chemotherapeutic agents. 
Given that normal brain tissue [9, 10], or benign tumours 
Figure 1: The FA pathway is highly expressed and active in high-grade gliomas, with FANCD2 expression associated 
with tumour grade. A: Representative images of FANCD2 staining in archived FFPE sections of schwannoma (negative control) and 
gliomas of various tumour grades as indicated. FANCD2 is a nuclear protein, which can be seen in the grade III and grade IV tumours 
shown (brown DAB staining). B: Quantification of FANCD2 expression in 131 schwannoma and gliomas of various tumour grades. A chi-
squared test was used to test for association with tumour grade. C: Representative images of FANCD2 staining in normal brain and gliomas 
of various tumour grade taken from commercial tissue microarray. Insert at bottom left of each image shows a magnified field from the 
section to show nuclear FANCD2 staining. The table underneath shows quantification of FANCD2 staining in the 36 samples present on 
the tissue microarray, indicating number of each sample exhibiting FANCD2 staining and the percentage of each tumour grade positive for 
FANCD2 expression. The percentage of FANCD2 positive tumours that also stained positive for Ki67 (supplementary Figure S1B) is also 
shown in the table. A chi-squared test was used to test for association with tumour grade. D: Western blots showing FANCD2 expression 
and activation (mono-ubiquitinated FANCD2; Ub-FANCD2) following Temozolomide (TMZ) treatment in two independently derived 
primary glioma cultures. To determine FA pathway activation, the normalised ratio of Ub-FANCD2 (L) to FANCD2 (S) was calculated for 
TMZ vs DMSO treated cells as previously described [30], and is shown under the blots as an L:S ratio. Also shown is MGMT expression 
and tubulin, which serves as a loading control.
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derived from a non-glial lineage (Figures 1A-B) do not 
express FANCD2, we postulate that inhibition of the 
FA pathway in high-grade gliomas represents a novel 
therapeutic window to improve the treatment of these 
incurable tumours.
Small molecule FA pathway inhibitors disrupt 
FA pathway activation in both established and 
primary glioblastoma cell cultures
Previous studies have demonstrated that the FA 
pathway is activated in response to chemotherapeutic 
agents currently used to treat GBM such as the alkylating 
agents Temozolomide (TMZ) and BCNU [18], and others 
have shown that FA-deficient cells are more sensitive to 
these agents than FA-proficient cells [18, 19]. However, 
the effects of several commercially available FA inhibitors 
(FAPi) in GBM cells have not been determined. We 
therefore used the glioma cell lines U87 and U138, which 
are respectively proficient and deficient for the FA pathway 
[18], to ascertain if FAPi can sensitise GBM cells to the 
chemotherapeutic agents currently used to treat high-grade 
gliomas. To date, four separate FAPi have been described 
that are commercially available; curcumin, its monoketone 
Figure 2: The FAPi curcumin, EF-24 and DDN inhibit FA pathway activation in immortalised and primary glioma 
cell cultures. A: Representative western blots showing FANCD2 and actin (loading control) expression in U87 (left panel) and U138 
cells (right panel). Treatment with Temozolomide (TMZ) activates the FA pathway as evidenced by the appearance of a slower migrating 
form of FANCD2 with represents the mono-ubiquitinated form (Ub-FANCD2). Pre-treatment with the indicated that FAPi severely inhibits 
FA pathway activation as evidenced by significantly reduced Ub-FANCD2 after TMZ treatment. DMSO treatments were used as negative 
controls. To determine FA pathway activation, the normalised ratio of Ub-FANCD2 (L) to FANCD2 (S) (normalised to DMSO+TMZ 
treated cells) was calculated for each treatment as previously described [30] and shown under the blots for U87 cells. Note that all values 
are zero for U138 cells). As described previously, U138 cells express low levels of FANCD2 and exhibit a defective FA pathway (no Ub-
FANCD2 after TMZ treatment). The FANCD2 antibody recognises a non-specific band in U138 cell line as indicated (n.s. band), which is 
most likely due to reduced epitope expression in this cell line. B: Immunofluorescence detection and quantification of cells exhibiting 10 
or more nuclear FANCD2 foci (a marker of an active FA pathway) in U87 and U138 cells treated as described above. Upper panel shows 
representative images for treated cells and the graph below show quantified data from at least three independent experiments. Error bars 
represent standard deviation of the means. C: Western blot showing FANCD2 expression and activation in a primary glioma culture. As 
with immortalised glioma cell lines, pre-treatment of the primary culture with the indicated FAPi compromises FA pathway activation as 
calculated by determining the normalised ratio of Ub-FANCD2 (L) to FANCD2 (S) as described in panel A. D: Quantification of FANCD2 
nuclear foci formation in 2 separate primary glioma cultures. Cells were either treated with DMSO (negative control) or TMZ, with or 
without pre-treatment with the indicated FAPi as described in the material and methods. Representative images for this data are shown in 
supplementary Figure S1D. Due to the difficulty in the long-term propagation of such cultures and their weak adherence on glass coverslips, 
error bars represent standard deviation of the means from 2 replica plates.
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analogues EF-24 & 4H-TTD, and the menadione analogue 
DDN [13-16]. However, in initial toxicity studies, we 
found that 4H-TTD was toxic to both U87 and U138 cells 
even at nM concentrations (data not shown), and was 
therefore excluded from our further analyses, as was the 
recently reported FAPi Ouabain [24]. 
Treatment of U87 cells with non-toxic doses of 
curcumin, EF-24 or DDN resulted in significant inhibition 
of FANCD2 mono-ubiquitination following treatment with 
TMZ (Figure 2A). This was accompanied by a concurrent 
reduction in the number of cells exhibiting FANCD2 
nuclear foci (Figure 2B). Consistent with a previously 
reported defective FA pathway [18], the glioma cell line 
U138 displayed reduced endogenous levels of FANCD2 
and an inability to activate the FA pathway following 
TMZ treatments (Figures 2A and 2B). Comparable data 
was obtained in both U87 and U138 cells using BCNU 
in place of TMZ (supplementary Figure S2A). It is 
important to note that the inhibitory effects on FA pathway 
activation conferred by curcumin, EF-24 or DDN were 
not a consequence of altered cell cycle distribution (data 
not shown). As well as serving as an important negative 
control for these experiments, the data generated in U138 
cells suggest that perturbation to FA pathway activity in 
U87 cells was a direct consequence of FAPi treatments, 
which was further confirmed using isogenic cell lines (see 
later). 
To ascertain if FAPi could inhibit the activation 
of the FA pathway observed in primary glioma cultures 
(Figure 1D), we treated several independently derived 
primary GBM cell cultures with TMZ with or without 
the prior treatment of FAPi. Consistent with results 
obtained in U87 cells, treatment of primary glioma cell 
cultures with curcumin, EF-24 and DDN all resulted 
in significant inhibition of FA pathway activation in 
response to Temozolomide treatments as measured by 
both reduced mono-ubiquitination of FANCD2 (Figure 
2C) and a reduced ability to form FANCD2 nuclear foci 
Figure 3: FAPi sensitise immortalised and primary glioma cultures to chemotherapeutic agents irrespective of MGMT 
status. A: MTT Temozolomide cytotoxicity assays for U87 and U138 cells treated with the FAPi curcumin, EF-24 or DDN. Solid lines 
represent cells pre-treated with DMSO and dashed lines represent cells pre-treated with the indicated FAPi. Data shown is the mean from 
at least 3 independent experiments with error bars representing the standard deviation of the means. B: MTT Temozolomide cytotoxicity 
assays for two independently derived primary glioma cultures from at least three independent experiments. An additional example is shown 
in supplementary Figure S2B. Solid, dashed lines and error bars are as described in panel A. C: MTT Temozolomide cytotoxicity assays 
for T98G cells pre-treated with either DMSO or the FAPi curcumin, EF-24 or DDN. Solid, dashed lines and error bars are as described in 
panel A.
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(Figures 2D and S1D). Together with the data presented 
in Figure 1, these results provide strong evidence that 
unlike normal brain tissue, an active FA pathway is highly 
expressed in high-grade gliomas and the use of FAPi may 
therefore sensitise these inherently resistant tumours to 
chemotherapeutic agents.
Inhibition of the FA pathway sensitises 
glioblastoma cells to chemotherapeutic agents 
irrespective of MGMT status
To determine if inhibition of the FA pathway could 
sensitise glioma cells to chemotherapeutic agents, we 
carried out cytotoxicity assays, initially using U87 (FA 
proficient) and U138 (FA deficient) cells. Cells were pre-
treated with the FAPi curcumin, EF-24 or DDN, and then 
treated with increasing doses of either TMZ or BCNU. 
All three FAPi conferred a significant increased sensitivity 
to both TMZ and BCNU in the FA-proficient U87 cells 
(Figure 3A and supplementary Figure S2B respectively). 
Importantly, this increased sensitivity could be mainly 
ascribed to inhibition of the FA pathway, rather than 
any non-specific activities of the FAPi, as comparable 
increased sensitivity was not observed in FA-deficient 
U138 cells treated with either curcumin of EF-24, with 
only a modest increase observed in DDN treated cells 
(Figure 3A and supplementary Figure S2B). In order to 
ascertain if inhibition of the FA pathway would also confer 
a chemo-sensitising phenotype to primary glioma cultures, 
we repeated these experiments using several primary 
glioma cultures derived from fresh tissue (supplementary 
Figure 1C). Consistent with data obtained in immortalised 
glioma cell lines (Figures 3A and S2B), and with the 
fact that FAPi are capable of inhibiting FA pathway 
activation in primary glioma cell lines (Figures 2C, 2D 
and S1D); pre-treatment with curcumin, EF-24 or DDN 
all led to significantly increased TMZ sensitivity in several 
independently derived primary GBM cultures (Figure 3B 
and supplementary Figure S2C). As with immortalised 
glioma cell lines, both EF-24 and DDN were generally 
greater chemo-sensitisers than curcumin, which likely 
reflects their increased potency to inhibit the FA pathway 
[15, 16]. 
Inherent resistance of high-grade gliomas to 
alkylating agents has often been linked to expression of 
the de-alkylating enzyme MGMT, which is not expressed 
in around half of these tumours [1]. However, conclusive 
evidence that such genetic differences account for the 
majority of tumour cell responses to such agents is still 
lacking and may also be linked to other DNA repair 
mechanisms [2]. If inhibition of the FA pathway is to 
offer promise as a potential chemo-sensitising strategy, 
Figure 4: Generation of isogenic FANCD2 proficient and deficient U87 cell lines and their use to determine FAPi 
specificity. A: Western blots showing FANCD2 expression in a number of stable shRNA expressing clones. Control cells represent those 
stably transfected with a non-targeting shRNA plasmid, while FANCD2 are clones derived from cells transfected with FANCD2-targeting 
shRNA plasmids. Actin is shown as a loading control and red asterisks highlight clones selected for use in further studies based on their 
residual FANCD2 levels. B: Western blot showing FANCD2 expression and activation (Ub-FANCD2) following Temozolomide treatment 
in the selected stable U87 clones outlined in panel A. C: MTT Temozolomide cytotoxicity assays for the selected stable U87 clones outlined 
in panel A pre-treated with either DMSO or the FAPi curcumin, EF-24 or DDN. Data shown was derived from at least three independent 
experiments and solid, dashed lines and error bars are as described in Figure 3A. 
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then it is important to determine if they confer this 
function irrespective of MGMT status. U87 cells are 
MGMT negative and U138 cells are MGMT positive 
(supplementary Figure S2D), therefore FAPi are capable 
of sensitising MGMT negative cells to both TMZ and 
BCNU (Figures 3A and S2B). To determine if they also 
act as potent chemo-sensitisers in an MGMT positive 
genetic background, we carried out cytotoxicity assays 
with the FAPi curcumin in T98G cells, which, like 
U87 cells are chemo-resistant, yet are MGMT positive 
(supplementary Figure S2D). Pre-incubation of T98G 
cells with curcumin, EF-24 or DDN all sensitised T98G 
cells to TMZ in a similar manner to that observed in the 
MGMT negative cell line U87 (Figure 3C). We therefore 
conclude that inhibition of the Fanconi Anaemia pathway 
offers promise as a chemo-sensitising strategy irrespective 
of MGMT status, which is an important finding for the 
future clinical development of FAPi. 
The use of FA-proficient and FA-deficient U87 and 
U138 GBM cell lines provides strong proof of concept that 
the observed increased sensitivity to chemotherapeutic 
agents is specifically due to inhibition of the FA pathway. 
However, other genetic differences between these two 
cell lines could account for some of the phenotypic 
differences observed, as could potential off-target effects 
of these FAPi [17, 25]. To provide more conclusive proof 
and to act as important tool for the further development 
of FAPi, we generated isogenic U87 cell lines that are 
proficient or deficient in the FA pathway. To achieve 
this, we stably integrated plasmids expressing previously 
validated FANCD2-directed shRNA and screened several 
clones derived from two independent shRNA or non-
targeted control shRNA for FANCD2 levels (data not 
shown). A cell line was selected that exhibited minimal 
residual FANCD2 expression and severely compromised 
FA pathway activation when compared to cell lines stably 
expressing non-targeted control shRNA (Figure 4A and 4B 
respectively). As in parental U87 cells, pre-treatment with 
the FAPi curcumin, EF-24 and DDN sensitised the stable 
cell line expressing a non-targeting control shRNA to 
TMZ treatments (Figure 4C). Importantly however, these 
FAPi had minimal effect of TMZ sensitisation in the cell 
line depleted of FANCD2 (Figure 4C). Similar data was 
obtained using an additional stable FANCD2-depleted cell 
line expressing shRNA targeting a different region of the 
FANCD2 mRNA (supplementary Figure S2E). The slight 
increased TMZ sensitivity observed in the FANCD2-
depleted cells following pre-treated with either EF-24 or 
DDN likely reflects their more potent activity towards 
the residual levels of FANCD2 compared to Curcumin 
[15, 16]. Collectively, these findings provide strong proof 
of concept data that FAPi could sensitise gliomas to 
chemotherapeutic agents by exploiting their heightened FA 
pathway expression/activity compared to the surrounding 
normal brain tissue.
DISCUSSION
We report here the first appraisal of the expression 
and activity of the FA pathway in high-grade glioma, 
demonstrating a strong association between FA protein 
expression and clinical grade. Given that the FA pathway 
is activated during normal S-phase transit (unperturbed 
DNA replication) or in response to replication-blocking 
lesions [4, 5, 7], increased FANCD2 expression in high-
grade glioma is most likely a consequence of an increased 
proliferative index, which also increases with glioma 
grade. Indeed, analyses of the proliferation marker Ki67 
in GBM tissue micro-arrays agree with this hypothesis 
(Figures 1C and S1C). It is interesting to note that in 
contrast to these findings, a previous study showed that a 
cohort of breast tumours exhibiting reduced cytoplasmic 
FANCD2 expression were correlated with poor survival 
outcomes [26]. However, our findings are also consistent 
with previous reports showing that highly proliferative 
tissues such as testis, tonsils and spleen exhibit high 
expression of FANCD2 and FANCA, yet non-proliferative 
tissues such as lung, liver, muscle and the brain exhibit 
minimal expression of these proteins [9, 10]. We also 
reveal that FANCD2 expression is negligible in normal 
brain tissue, which is consistent with previous findings 
that the FA pathway is down regulated in differentiated 
cells [8]. Also relevant to our findings is a recent large-
scale gene expression study which revealed that at least 
12 of the currently 16 known FA genes exhibit increased 
expression at the mRNA level in GBM compared to 
normal brain tissue [11]. Taken together, the data presented 
here are in agreement with previous studies and reveal an 
exploitable therapeutic window for FA pathway inhibition 
in high-grade gliomas. In this regard, and as part of our 
on-going studies towards such clinical application of FA 
pathway inhibitors, we also report here the first use of 
multiple commercially available FAPi (curcumin, EF-24, 
DDN) to sensitise glioma cells to chemotherapeutic agents 
irrespective of genetic background. 
An important aspect to bear in mind when 
considering clinical applications of FA pathway inhibitors 
is how such FAPi will be delivered to prevent/minimise 
possible systemic side effects. The recent interest and 
advancements in nano-particles combined with magnetic-
mediated delivery/localisation is a potentially attractive 
future approach for drug delivery in glioma. Indeed, it has 
been recently reported that curcumin and Temozolomide 
could be successfully co-loaded onto such particles and 
delivered to both 2D and 3D model cell cultures [27]. 
Alternatively, oral delivery of an FAPi such as curcumin 
may offer a viable and safe delivery mechanism [28], 
assuming of course that sufficiently amounts of active 
compound at the tumour site could be achieved to confer 
a chemo-sensitising effect. 
Perhaps the most promising approach would either 
be the use of current intrathecal pumps to facilitate 
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exploitation of the blood-brain barrier to deliver FAPi 
directly into the cerebrospinal fluid or alternatively 
intratumoural/intracerebral convection enhanced delivery 
[29]. Thus, delivery of small-molecule FA pathway 
inhibitors directly to the cerebrospinal fluid or directly 
into the brain parenchyma may maximise their sensitising 
properties at tumour sites, whilst taking advantage of the 
blood-brain barrier to retain the FAPi agent to minimise 
possible systemic side effects. Such an approach would 
therefore facilitate both tumour localisation and reduce 
potential undesired side effects. 
Given that the mechanisms of action for any of the 
commercially available FAPi described here (curcumin, 
EF-24 and DDN) are currently unknown; as part of the 
future development of more potent and specific FAPi, we 
are presently working with medicinal chemists to develop 
novel small molecule inhibitors of the FA pathways for 
which we know the mechanism of action. The isogenic 
FANCD2 proficient/deficient U87 cells lines described 
here, along with others that we are presently generating 
will be instrumental in determining FAPi specificity and 
for target validation studies. To facilitate this potential 
future application of FAPi, we are also currently carrying 
out in vivo studies based on the promising in vitro findings 
presented here, using both commercially available FAPi 
and our novel FAPi in combination with chemotherapeutic 
agents currently used in the clinical management of high-
grade gliomas. Given the poor prognosis of patients with 
high-grade gliomas and the current unmet need for new 
therapies for this devastating disease, it is hoped that the 
data presented here and future in vivo studies will facilitate 
the development of an early phase clinical trial to allow 
the assessment of the use of FAPi to improve our current 
treatment of these tumours.
MATERIALS AND METHODS
Primary and archived brain tumour samples
Primary brain tumour tissue surplus to clinical 
requirements was collected from patients attending the 
Neuro-oncology unit at the Sheffield Royal Hallamshire 
Hospital, and FFPE tissue was retrieved from the Royal 
Hallamshire Hospital diagnostic archive. The research 
involving patient material was approved by the Leeds 
East Research Ethics Committee (REC reference 11/
YH/0319). The tissue microarray containing both healthy 
and cancerous human brain tissue cores was purchased 
from Insight Biotechnology. All archived brain tissue 
were verified for tumour grade by a consultant pathologist 
(MF).
Cell Culture
Genetically authenticated U87, U138 and T98G 
cells were obtained from ATCC and maintained as 
adherent monolayer cultures in DMEM media containing 
10% FBS at 37°C in a humidified atmosphere of 5% 
carbon dioxide, and sub-cultured when ~70% confluence 
was reached. Both serum-free and serum-adapted cell 
cultures derived from primary GBM tissue were prepared 
as previously described [21, 22] under appropriate ethics 
approval (REC reference 11/YH/0319). Stable FANCD2-
deficient U87 cells were created using the HuSH shRNA 
system from Origene as described in the manufacturers 
protocol. 
Antibodies
FANCA (IHC: ab5063, 1:100), FANCD2 (IHC: 
ab108928, 1:200; IF: ab2187, 1:1000; WB: ab12450, 
1:5000) and MGMT (ab39253, 1:1000), Ki67 (ab16667, 
1:100). For Western blotting, primary antibodies were 
visualised using HRP-conjugated anti-rabbit and anti-
mouse secondary antibodies at 1:5000 (DAKO P0399 
and P0447 respectively). For immunofluorescence, anti-
mouse Alexa-488 or anti-rabbit Alexa-594 (Invitrogen) 
were used at 1:1000. The FANCD2 antibody for IHC 
was optimised using mouse spleen and brain as positive 
and negative controls for protein expression respectively 
(supplementary Figure S1A) as previously described [9], 
together with FANCD2 proficient and siRNA-depleted 
cells (data not shown).
Drug treatments
Cells were treated with Curcumin (5µM), EF-
24 (31nM), DDN (30nM) 8 hours prior to treatment 
with 50µM of either TMZ or BCNU for 24hrs (western 
blots and immunofluorescence detection of FA pathway 
activation) or 5 days (cytotoxicity assays).
Cell lysis and Western Blotting
For whole-cell extracts, cells were solubilized on 
ice for 20 minutes in lysis buffer; 20 mM Tris-HCl pH 
7.5, 150 mM NaCl, 1% Triton X-100, 1 mM DTT and 
1 mM EDTA supplemented with 50 U/μl benzonase 
(Novagen), protease and phosphatase inhibitors (Sigma). 
Cleared lysates were produced by centrifugation of the 
resulting samples at 16,000 × g for 15 min at 4°C. Gel 
electrophoresis was performed using the NuPAGE system 
(Invitrogen). Briefly, samples were resolved on 4-12% 
Bis-Tris gels in MOPS buffer, transferred to a PVDF 
membrane which was then probed for the protein of 
interest using antibodies diluted in PBS containing 5% 
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Marvel and 0.1% Tween-20 (Sigma).
Immunohistochemistry and scoring
Formalin fixed paraffin embedded (FFPE) samples 
were deparaffinised in 2 xylene baths for 5-10 minutes 
each. Slides were then hydrated through descending 
grades of ethanol (100% to 70%) for 3 minutes each. 
After washing the slides in running water for 5 minutes, 
the sections were then immersed in sodium citrate at 
pH 6 (Sigma) and microwaved for 3 minutes at high 
temperature and 7 minutes at low temperature for antigen 
retrieval. The slides were allowed to cool down in solution 
and then washed in distilled water for 15 minutes. Sections 
were then soaked in 3% hydrogen peroxide in methanol 
at 37°C for 30 minutes to block endogenous peroxidase 
activity. Following 3 washes in distilled water, slides 
were then incubated for 60 minutes in 10 % normal goat 
serum (Vector Laboratories) and 10% casein in PBS to 
block non-specific binding sites and then probed with the 
relevant primary antibodies prepared in PBS containing 
2% sera and 2% casein overnight at 4°C. Next day, slides 
were rinsed in PBS and then incubated for 60 minutes 
at room temperature in biotinylated goat anti-rabbit 
secondary antibody (Vector Laboratories) prepared at 
1:200 in PBS containing 2% sera and 2% casein. The 
antigen-antibody complexes were detected using the 
Vectastain Elite ABC kit (Vector Laboratories) according 
to manufacturer’s protocol, followed by staining with 
3,3’-diaminobenzidin (DAB) peroxidase substrate kit, 
(Vector Laboratories). Sections were then counterstained 
in Gill’s haematoxylin and dehydrated in ascending grades 
of ethanol before clearing in xylene and mounting under 
a coverslip using DPX mountant (Fisher). All sections 
were verified for tumour grade by a consultant pathologist 
(MF), who also marked the tumour area for scoring. 
Scoring of FANCD2 staining was carried out blindly by 
two independent people (AAP and AR), with positive 
staining indicating that ≥50% cells in the marked tumour 
area had positively stained nuclei. A chi-squared test was 
used to test for association with tumour grade.
Immunofluorescence
Cells were grown on glass coverslips and treated as 
indicated, then fixed with 3% buffered paraformaldehyde 
for 10 min at RT, and permeabilized in PBS containing 
0.5% Triton X-100 for 5 min at RT. Cells were then 
incubated with primary antibody for 2 hrs at RT, and 
detected with a secondary Alexa-488 or Alexa-594 
conjugated goat anti-rabbit or anti-mouse IgG. Antibody 
dilutions and washes after incubations were performed 
in PBS. DNA was stained with DAPI (1 µg/ml) and 
coverslips were mounted in Shandon Immu-Mount 
medium (Thermo). Fluorescence microscopy was 
performed on a Nikon Eclipse T200 inverted microscope 
(Melville), equipped with a Hamamatsu Orca ER camera 
and a 200 W metal arc lamp (Prior Scientific, United 
Kingdom), with a 60X and 100X objective lens. Images 
were captured and analyzed using Volocity software 
(Improvision). 
Flow Cytometric Analyses
Cells were collected using trypsin, pelleted, washed 
with PBS, fixed in 70% ice-cold ethanol, and stored at 
−20°C for up to 2 weeks. After thoroughly washing with 
PBS, to remove any residual ethanol, cells were stained 
with a propidium iodide solution (50 µg/ml) containing 
RNase A (25 µg/ml) for 30 min before flow cytometry 
was performed on a Becton Dickinson FACScalibur 
instrument. The percentage of cells in each cell cycle 
phase was subsequently calculated using FloJo analysis 
software.
Cytotoxicity assays
Cells were plated at a density of between 1000-
2000 cells/well in 96-well plates (depending on cell line), 
and the following day treated with appropriate non-toxic 
concentrations of FAPi for 8 hours, after which time, cells 
were then treated with DMSO, TMZ or BCNU. After 5 
days of growth, MTT reagent was added to the cells at 
a final concentration of 3 mg/ml, and incubated at 37°C 
for 3 hrs. The media was removed and replaced with 200 
µl DMSO to solubilise the formazan product, which was 
quantified by determining optical density at 540 nm using 
a spectrophotometric microtitre plate reader. Cytotoxicity 
was calculated for each treatment by normalisation to 
appropriate vehicle only (DMSO-treated) controls.
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